Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürstenwalde – page 134

1 727 clinical trials in Fürstenwalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürstenwalde at a glance
1 727
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 727 trials in Fürstenwalde

Open in trial search

Study on the Effects of EP262 for Adults with Chronic Spontaneous Urticaria

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:EP262
  • Sponsor:Escient Pharmaceuticals Inc.

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Nicotine dependence

Not recruiting

Study on Nicotine Freshmint Mouthspray for E-cigarette Users Looking to Quit

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nicotine
  • Sponsor:McNeil AB

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic hepatitis B+1

Not recruiting

Study of Bepirovirsen for Patients with Chronic Hepatitis B on Nucleos(t)ide Analogue Treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Filgotinib for Children and Teens with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Neoplasm malignant+1

Not recruiting

Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

HIV infection

Not recruiting

Study Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

Androgenetic alopecia

Not recruiting

Study on the Effectiveness and Safety of Oral Minoxidil for Women with Androgenetic Alopecia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Minoxidil
  • Sponsor:Industrial Farmaceutica Cantabria S.A.

Study on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Medical University Of Vienna

Cardiac amyloidosis

Not recruiting

Study on the Use of Florbetaben (18F) PET Imaging for Diagnosing Cardiac AL Amyloidosis in Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Lantheus Germany GmbH

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürstenwalde

What the registry says about research in the country

01 Respiratory Tract Diseases

Clinical research in Fürstenwalde Spree is focused on respiratory tract diseases, with all active studies centered on asthma and its more severe forms. These trials are looking at new treatment options, safety, and signs of better disease control for people with difficult-to-manage asthma.

  • Asthma and uncontrolled asthma
  • Severe eosinophilic asthma and eosinophilic phenotype
  • Moderate to severe controlled asthma under current guideline-based care
  • Testing new therapies and comparing them with existing treatments

The research includes studies of inhaled and biologic approaches, with an emphasis on improving symptom control, evaluating long-term safety, and measuring airway inflammation markers.

02 Asthma Treatment Safety and Tolerability

One part of the local trial landscape examines how well new asthma treatments are tolerated, especially in people already living with persistent disease. These studies help determine whether emerging options can offer benefits while remaining safe for everyday use.

  • Asthma treatment safety
  • Comparing different inhaled therapy formulations
  • Assessing long-term safety in ongoing care

This work supports clearer decisions about whether new therapies can be used comfortably and reliably in routine respiratory medicine.

03 Severe Eosinophilic Asthma

Several studies are dedicated to severe eosinophilic asthma, a more advanced form of asthma linked to ongoing inflammation. The goal is to see whether newer biologic treatments can improve control for patients who have already responded to specialized care.

  • Severe eosinophilic asthma
  • Evaluating biologic treatments for better disease control
  • Studying patients who benefited from prior anti-IL-5 or anti-IL-5R therapy

These trials aim to refine treatment choices for people with persistent eosinophilic airway inflammation and ongoing symptoms.

04 Biologic Therapies for Asthma

The research portfolio also includes studies of targeted biologic therapies for asthma, especially for patients with frequent symptoms or severe inflammatory disease. These trials are designed to test whether newer medicines can offer stronger and longer-lasting benefit than current options.

  • Biologic treatment strategies
  • Severe asthma management
  • Comparing new targeted therapies with established care

This area highlights a broader move toward more precise respiratory research that matches therapy to the underlying disease pattern.

05 Inflammation Markers and Asthma Control

Another important focus is the study of markers that reflect airway inflammation in asthma. By observing changes such as FeNO, researchers can better understand how well a treatment is affecting the underlying disease process.

  • Fraction of exhaled nitric oxide (FeNO)
  • Uncontrolled asthma
  • Evaluating whether new therapy can reduce airway inflammation

This kind of research helps improve both diagnosis and treatment monitoring in respiratory tract disease care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.